A Review on Nitrosamine Impurities in Pharmaceutical Products

Review Article

Abstract

Nitrosamine impurities in pharmaceutical products could be a critical quality concern since their initial detection in sartan-based medications in 2018. These genotoxic compounds can form during drug synthesis, manufacturing, storage, or degradation through various pathways involving secondary or tertiary amines and nitrosating agents. The acceptable daily intake limit of 26.5 nanograms established by regulatory authorities reflects the serious carcinogenic potential of these compounds. Multiple analytical techniques including LC-MS/MS, GC-MS, and HPLC have been developed and validated for detecting trace levels of nitrosamines such as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) in pharmaceutical products. Root cause investigations have identified several factors contributing to nitrosamine formation, including contaminated raw materials, degradation of solvents like DMF, cross-contamination during manufacturing, and API instability. Prevention strategies focus on controlling nitrosating conditions, using nitrite scavengers like ascorbic acid and α-tocopherol, and implementing robust analytical testing protocols. Recent cases involving valsartan, ranitidine, and metformin have led to significant regulatory oversight and development of control frameworks. The knowledge of formation mechanisms combined with sensitive analytical methods and preventive measures continues to evolve to ensure patient safety through elimination of these harmful impurities from pharmaceutical products